Announcements Trials
Browse Landscape

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 56Observational 3Expanded_access 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Metastatic Castration-resistant Prostate Cancer 1

Interventions

Surveys and Questionnaires 52Blood Specimen Collection 47enzalutamide 29radium Ra 223 dichloride 22Biopsy 20darolutamide 19Radiotherapy 19Docetaxel 19apalutamide 18Sunitinib 18Magnetic Resonance Spectroscopy 18Sorafenib 17Abiraterone Acetate 17Watchful Waiting 16Interviews as Topic 15Gene Expression Profiling 15Amplified Fragment Length Polymorphism Analysis 15Observation 13Leuprolide 13Immunohistochemistry 13Androgen Antagonists 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 12Magnetic Resonance Imaging 12avelumab 11Specimen Handling 11abiraterone 9Polymerase Chain Reaction 9Flow Cytometry 9Radiosurgery 8Microarray Analysis 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Pluvicto × Genitourinary × Clear all
NCT06389097 2026-03-30

(SEEtoTREAT)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Recruiting
80 enrolled
Genitourinary

Prostatic Neoplasms

NCT06514521 2025-12-30

Post Marketing Study on Pluvicto in Korea

Novartis

Recruiting
278 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06461689 2025-03-04

PROLUT

Central Hospital, Nancy, France

Completed
80 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡